JP2017514820A - アルカプトン尿症を治療するためのニチシノン投薬処方 - Google Patents

アルカプトン尿症を治療するためのニチシノン投薬処方 Download PDF

Info

Publication number
JP2017514820A
JP2017514820A JP2016564948A JP2016564948A JP2017514820A JP 2017514820 A JP2017514820 A JP 2017514820A JP 2016564948 A JP2016564948 A JP 2016564948A JP 2016564948 A JP2016564948 A JP 2016564948A JP 2017514820 A JP2017514820 A JP 2017514820A
Authority
JP
Japan
Prior art keywords
nitisinone
dosage
hga
administered
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016564948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514820A5 (enExample
Inventor
オルソン ブリギッタ
オルソン ブリギッタ
Original Assignee
スウェディッシュ オーファン バイオビトラム インターナショナル アクティエボラーグ
スウェディッシュ オーファン バイオビトラム インターナショナル アクティエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スウェディッシュ オーファン バイオビトラム インターナショナル アクティエボラーグ, スウェディッシュ オーファン バイオビトラム インターナショナル アクティエボラーグ filed Critical スウェディッシュ オーファン バイオビトラム インターナショナル アクティエボラーグ
Publication of JP2017514820A publication Critical patent/JP2017514820A/ja
Publication of JP2017514820A5 publication Critical patent/JP2017514820A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016564948A 2014-04-30 2015-04-29 アルカプトン尿症を治療するためのニチシノン投薬処方 Pending JP2017514820A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1450521-8 2014-04-30
SE1450521 2014-04-30
PCT/EP2015/059352 WO2015165972A1 (en) 2014-04-30 2015-04-29 Nitisinone dosing regimens for the treatment of alkaptonuria

Publications (2)

Publication Number Publication Date
JP2017514820A true JP2017514820A (ja) 2017-06-08
JP2017514820A5 JP2017514820A5 (enExample) 2018-05-24

Family

ID=53175441

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564948A Pending JP2017514820A (ja) 2014-04-30 2015-04-29 アルカプトン尿症を治療するためのニチシノン投薬処方

Country Status (11)

Country Link
US (1) US20170049716A1 (enExample)
EP (1) EP3137066A1 (enExample)
JP (1) JP2017514820A (enExample)
AU (1) AU2015254669A1 (enExample)
BR (1) BR112016024756A2 (enExample)
CA (1) CA2947062A1 (enExample)
IL (1) IL248506A0 (enExample)
MA (1) MA39918A (enExample)
SG (1) SG11201608957VA (enExample)
TN (1) TN2016000479A1 (enExample)
WO (1) WO2015165972A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838039C (en) * 2011-06-23 2017-10-24 Swedish Orphan Biovitrum International Ab Liquid pharmaceutical composition comprising nitisinone

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F BENDADI ET AL.: "Impaired Cognitive Functioning in Patients with Tyrosinemia Type I Receiving Nitisinone", JOURNAL OF PEDIATRICS, vol. 164(2), JPN6018049869, February 2014 (2014-02-01), pages 398 - 401, ISSN: 0003942084 *
W J. INTRONE ET AL.: "A 3-year Randomized Therapeutic Trial of Nitisinone in Alkaptonuria", MOL GENET METAB., vol. 103(4), JPN6018049867, 2011, pages 307 - 314, ISSN: 0003942083 *

Also Published As

Publication number Publication date
SG11201608957VA (en) 2016-11-29
MA39918A (fr) 2017-03-08
EP3137066A1 (en) 2017-03-08
WO2015165972A1 (en) 2015-11-05
IL248506A0 (en) 2016-12-29
BR112016024756A2 (pt) 2017-08-15
AU2015254669A1 (en) 2016-12-15
US20170049716A1 (en) 2017-02-23
CA2947062A1 (en) 2015-11-05
TN2016000479A1 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
US20190083388A1 (en) Synthentic transdermal cannabidiol for the treatment of focal epilepsy in adults
KR102547164B1 (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
JP2023065398A (ja) リルゾールの舌下製剤
US20200101067A1 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
US20250188158A1 (en) Treatment of Parkinson's Disease
AU2021281118A1 (en) Treatment of autism spectrum disorder with cannabidiol
JP2022546456A (ja) 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
US20060194822A1 (en) Treatment for renal fibrosis
KR20230106644A (ko) S1p1 수용체와 관련된 상태를 치료하는 방법
US20050009813A1 (en) Use of desoxypeganine for treating clinical depression
US10300068B2 (en) Method of treating insomnia
JP2017514820A (ja) アルカプトン尿症を治療するためのニチシノン投薬処方
TW202415377A (zh) 治療化膿性汗腺炎之方法
EP3131545A2 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
RU2499597C2 (ru) Способ лечения и профилактики назальной обструкции у больных полипозным риносинуситом
Ghimire et al. Comparative efficacy of steroid nasal spray versus antihistamine nasal spray in allergic rhinitis
RU2847397C2 (ru) Лечение кожной формы красной волчанки
JP2024538054A (ja) 高シュウ酸尿症及び腎結石の治療のための1h-1,2,3-トリアゾール-4-カルボン酸
EP4403181A1 (en) A medicinal product for use in administering in the treatment, control and/or prevention of pain
AU2024238367A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
US20250177322A1 (en) Treatment of fragile x syndrome with cannabidiol
Funahashi et al. SAT0088 COMPARISON OF THE INITIAL DIAGNOSTIC FINDINGS AND ONSET FACTORS OF RHEUMATOID ARTHRITIS (RA) IN ELDERLY ONSET RA AND ADULT ONSET RA BY MULTICENTER COHORT–ARE THERE ANY DIFFERENCES OF ONSET FACTORS?–
US20120172390A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem
To et al. Serotonergic and Dopaminergic Agents Facilitate Rehabilitation Following Hypoxic Brain Injury
HK40003409A (en) Treatment of prurigo nodularis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180403

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190723